Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

Trial Profile

Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Vonapanitase (Primary)
  • Indications Thrombosis; Vascular disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms PATENCY-2
  • Sponsors Proteon Therapeutics
  • Most Recent Events

    • 14 Mar 2018 According to a Proteon Therapeutics media release, topline results from the study are expected in April 2019.The BLA submission for vonapanitase to FDA is expected in the fourth quarter of 2019.
    • 05 Mar 2018 According to a Proteon Therapeutics media release, based on the successful results of this trial, the company expects to submit a Biologics License Application (BLA) for vonapanitase to the U.S. Food and Drug Administration (FDA) in 2019.
    • 05 Mar 2018 According to a Proteon Therapeutics media release, top-line data from this trial is expected in March of 2019. 603 patients have been treated in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top